Raymond James Financial
IMDX

Raymond James Financial’s Insight Molecular Diagnostics IMDX Stock Holding History

Raymond James Financial’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,189
Closed -$3.59K – 6169
2025
Q2 		$3.59K Buy
+1,189
New +$3.59K ﹤0.01% 6265

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's IMDX Position: Q3 2025 in Review

Raymond James Financial sold out of Insight Molecular Diagnostics (IMDX) in Q3 2025, closing a stake of 1,189 shares — an estimated $3.59K sold.

Raymond James Financial first reported a position in IMDX in Q2 2025 and held it in 1 quarter. The position peaked at $3.59K in Q2 2025. 27 funds tracked by Wall St. Rank hold IMDX as of Q3 2025.

  • Raymond James Financial reported no remaining Insight Molecular Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,189 Insight Molecular Diagnostics shares in Q3 2025, an estimated $3.59K.
  • Raymond James Financial first reported a position in Insight Molecular Diagnostics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Insight Molecular Diagnostics position peaked at $3.59K in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.